Our Recent Article in ploseone

A novel gamma radiation-inactivated sabin-based polio vaccine

A concerted action on the part of international agencies and national governments has resulted in the near-eradication of poliomyelitis. However, both the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV) have deficiencies which make them suboptimal for use after global eradication. OPV is composed of attenuated Sabin strains and stimulates robust immunity, but may revert to neurovirulent forms in the intestine which can be shed and infect susceptible contacts. The majority of IPV products are manufactured using pathogenic strains inactivated with formalin. Upon eradication, the production of large quantities of pathogenic virus will present an increased biosecurity hazard. A logical ideal endgame vaccine would be an inactivated form of an attenuated strain that could afford protective immunity while safely producing larger numbers of doses per unit of virus stock than current vaccines.

Click here to read the full article.

 BMI is a innov
ative, privately-held vaccine design and development company located in Frederick, Maryland, USA.
Contact Us     Email: polio@bmi-md.com      Phone: (301) 378-2551  Info: Download White Paper
Download our recent publication in PLOS ONE describing the inactivation of polio using gamma irradiation: Click here.

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.